Canada markets close in 4 hours 40 minutes

Dynavax Technologies Corporation (DVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2500+0.1000 (+2.41%)
At close: 4:00PM EST
Sign in to post a message.
  • D
    Drunkard
    If this news from November 5th about Clover was posted here already, I must have missed it. Until it's fully understood what direction Clover is going with an adjuvant, it's all speculation obviously - but still interesting timeline nonetheless. Dates below:

    -March 24th, Dynavax and Clover announce a research collaboration.
    -June 19th, first patients dosed with Clover vaccine using CpG 1018
    -July 8th, CEPI announces $66Mill grant to Clover to rapidly advance the development and manufacture of Clover’s protein-based COVID-19 S-Trimer vaccine candidate
    -August 13th, it's announced Gates foundation issues a $3.4Mill grant to Dynavax to scale up production batch size for CpG 1018

    -Nov 5th, CEPI extends overall partnership with Clover from $70Mill to $328Mill
    "...to include funding for a global phase 2/3 efficacy clinical trial and licensure of its S-Trimer COVID-19 vaccine candidate.
    S-Trimer is a protein-based vaccine previously funded by CEPI. The coalition assisted it with $69.5 million meant to get it through preclinical studies and phase one clinical trials. After this latest expansion of assistance, CEPI’s total investment in the candidate will be up to $328 million. As a result of that investment, the drug will be made available for procurement and allocation through the COVAX Facility, a global initiative to procure and distribute 2 billion doses of COVID-19 vaccine by the end of 2021."
  • s
    sleestack76
    5 bucks coming....shorts covered some but have a long way to go. May take several months to hit 6 bucks.
  • K
    K
    So if the Clover Biopharmaceutical S-trimer vaccine is successful, it will manufacture hundreds of millions of doses. as part of TWO BILLION

    CEPI and Clover are committed to ensuring equitable global access to the S-Trimer vaccine, and the agreement therefore anticipates that vaccine output funded by CEPI’s investment – potentially hundreds of millions of doses per year – will be made available for procurement and allocation through the COVAX Facility. The COVAX Facility is a global initiative which aims to procure and fairly distribute two billion doses of COVID-19 vaccine by the end of 2021, to help protect the most at-risk groups in all participating countries.
  • M
    Mike
    Metronic Global Bhd (MGB) through its subsidiary Metronic Medicare Sdn Bhd (MMSB), has inked a memorandum of agreement (MoA) with Medigen Vaccine Biologics Corporation (MVC), to distribute Covid-19 vaccine in Malaysia and potentially other countries.

    Good news for both MVC as well as DVAX, 3 million doses.
  • j
    jesus
    It would be nice to see Clover continues the phase 2/3 with 1018. I guess that would be the best news we can expect in 2020
  • Y
    YRUNVS
    it seems like the adjuvant may not be as good as expect, given the share price has fallen a lot lately. you figure if the adjuvant was effective, the share price would reflect that. It maybe early to assume this, but i am hoping for the success of the adjuvant. for mankinds sake.
  • R
    RogerR
    DVAX may be needed:

    SINGAPORE/BEIJING, Nov 18 (Reuters) - Sinovac Biotech's experimental COVID-19 vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, preliminary trial results showed on Wednesday.
  • c
    ctic_neutral
    Previous options died for $300 loss. Picked up these on expectation of trial results:

    Buy 20 DVAX Dec 18 '20 $6 Call Executed @ $0.05 11/24/2020, 10:10:19 AM
  • G
    G
    nstitutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Hedge funds don't have many shares in Dynavax Technologies. The company's largest shareholder is State Street Global Advisors, Inc., with ownership of 11%. Federated Hermes, Inc. is the second largest shareholder owning 10% of common stock, and Bain Capital Life Sciences Investors, LLC holds about 9.9% of the company stock. Do you want to bet against these giants. I think not.
  • G
    Glenn
    Fantastic, great reversal, something is on the horizon..Friday, Monday big news! stay tuned for acquisition news!
  • K
    K
    SARS-CoV-2 spike protein, S-2P. To enhance immunogenicity and mitigate the potential vaccine-induced immunopathology, CpG 1018, a Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an adjuvant candidate. S-2P in combination with CpG 1018 and aluminum hydroxide (alum) was found to be the most potent immunogen and induced high titer of neutralizing antibodies
  • R
    RogerR
    Medigen animal data in peer review article NatureDOTcom

    It verifies the rationale for CpG 1018.

    Title: Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19

    Yahoo does not allow the link.
  • K
    K
    India pins hopes on locally-tested COVID-19 vaccines given Pfizer constraints
    8:53am ET, 11/17/2020 - Reuters
    By Krishna N. Das

    NEW DELHI, Nov 17 (Reuters) - India hopes five locally-tested vaccines will help it to control COVID-19, as those developed by Pfizer and Moderna may not be available to it in big quantities soon.

    The five candidates include Russia's Sputnik-V whose "Phase-II going to Phase-III" trials in India will start next week in collaboration with Dr Reddy's Laboratories, Vinod Paul, the head of a committee advising the prime minister, said.

    The other experimental vaccines are the one being developed by AstraZeneca and Oxford University which is being manufactured by the Serum Institute of India; Bharat Biotech and the Indian government's COVAXIN; Zydus Cadila's ZyCoV-D and lastly one being developed by Biological E. Ltd alongside Baylor College of Medicine and Dynavax Technologies Corp.
  • K
    Kitcheyan
    Check out (http://Pick-stocks.com). They just mentioned DVAX in the daily newsletter.
  • L
    Lynn
    Dr Peter Hotez mentioned “their vaccine” today on MSNBC. He did not mention Dvax though.
  • J
    James
    What we don’t really know of the Pfizer and Moderna results is what it the transmission rates when masks, social distancing, etc measures are not in place. Moderna had 90 out of 15K get sick who took the placebo and 5 out of 15K that took the vaccine. What does that 5 figure jump up to under life as normal and how long is one protected.
  • A
    A1
    Time is Ticking...

    Soon you could wake up to 10 very quick...

    GL

    A1
  • b
    breezerwave
    "Initial CpG 1018 revenue and deferred revenue totaling $23.4 million in third quarter, with potential 2021 revenue between approximately $130 to $230 million"

    "Third quarter 2020 HEPLISAV-B® net product revenue highest since launch at $11.6 million, despite impact of COVID-19"'

    While posted just a few days ago good summary by DVAX including Covid-19 trials with CpG 1018 from DVAX being used and the current trial status. Good information for anyone that may be recently reading information on this board.

    https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-third-quarter-2020-financial-results
    The Investor Relations website contains information about Dynavax Technologies Corporation's business for stockholders, potential investors, and financial analysts.
    The Investor Relations website contains information about Dynavax Technologies Corporation's business for stockholders, potential investors, and financial analysts.
    investors.dynavax.com
  • R
    RogerR
    University of Colorado supports CpG 1018 for a COVID vaccine.  Their neighbor, BARDA, may be interested.
     
    As part of these studies, we also utilized adjuvant formulations intended to drive immune response to vaccines predominantly via a Th1  immune  pathway  [17,18]. Our  motivation  for employing  this  approach  was  generated  by  previous  observations  of  antibody  dependent enhancement (ADE) and resulting immunopathology in animal models where Th2 type immune stimulation predominated. We monitored immune response via cellular and humoral pathways in adjuvanted and non-adjuvanted formulations. We also monitored lung histopathology for evidence indicative of immunopathology induced by the virus or subsequent challenge post-vaccination.
    RESULTS
    Moreover, there was a significant decrease in viral titers in the CpG group within the IM subgroup demonstrating  that the IM  injection  of  SolaVAX+CpG  1018  offered  the  best  protection against viral replication in nasal turbinates.
     
    https://www.biorxiv.org/
    Welcome to the bioRxiv homepage.
    Welcome to the bioRxiv homepage.
    www.biorxiv.org
  • Y
    YRUNVS
    NICE NEWS,

    Analysts Just Shipped A Dazzling Upgrade To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Estimates
    Simply Wall St
    Tue, November 10, 2020, 5:33 AM EST

    Celebrations may be in order for Dynavax Technologies Corporation (NASDAQ:DVAX) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals.

    After this upgrade, Dynavax Technologies' four analysts are now forecasting revenues of US$117m in 2021. This would be a huge 210% improvement in sales compared to the last 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 50% to US$0.51. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$74m and losses of US$0.65 per share in 2021. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to next year's revenue estimates, while at the same time reducing their loss estimates.